Cover Image
市場調查報告書

腹部主動脈血管瘤:開發中產品分析

Aortic Aneurysm - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 302497
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
腹部主動脈血管瘤:開發中產品分析 Aortic Aneurysm - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 47 Pages
簡介

所謂腹部主動脈血管瘤是主動脈血管壁腫起造成脆弱化,結果造成管直徑病態性擴大的症狀。主要的症狀有持續性的背痛和腹痛,發汗·冷汗,心律上升,暈眩等。主要的易罹病素質有年齡和動脈粥樣硬化,抽煙,家族病史等。

本報告提供全球各國治療腹部主動脈血管瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

腹部主動脈血管瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腹部主動脈血管瘤:企業開發中的治療藥

腹部主動脈血管瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腹部主動脈血管瘤:企業開發中的產品

腹部主動脈血管瘤的治療藥的開發企業

  • AstraZeneca Plc
  • Carolus Therapeutics, Inc.
  • Novartis AG
  • Vida Therapeutics Inc.

腹部主動脈血管瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BSN-908
  • canakinumab
  • CT-2009
  • ticagrelor
  • VTI-2000 Series
  • VTI-3000 Series

腹部主動脈血管瘤:最近的開發平台趨勢

腹部主動脈血管瘤:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7127IDB

Summary

Global Markets Direct's, 'Aortic Aneurysm - Pipeline Review, H2 2015', provides an overview of the Aortic Aneurysm's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aortic Aneurysm, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aortic Aneurysm and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Aortic Aneurysm
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Aortic Aneurysm and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Aortic Aneurysm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Aortic Aneurysm pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Aortic Aneurysm
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Aortic Aneurysm pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Aortic Aneurysm Overview
  • Therapeutics Development
    • Pipeline Products for Aortic Aneurysm - Overview
    • Pipeline Products for Aortic Aneurysm - Comparative Analysis
  • Aortic Aneurysm - Therapeutics under Development by Companies
  • Aortic Aneurysm - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Aortic Aneurysm - Products under Development by Companies
  • Aortic Aneurysm - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Carolus Therapeutics, Inc.
    • Novartis AG
    • Vida Therapeutics Inc.
  • Aortic Aneurysm - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BSN-908 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-2009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTI-2000 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTI-3000 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aortic Aneurysm - Recent Pipeline Updates
  • Aortic Aneurysm - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Aortic Aneurysm, H2 2015
  • Number of Products under Development for Aortic Aneurysm - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Aortic Aneurysm - Pipeline by AstraZeneca Plc, H2 2015
  • Aortic Aneurysm - Pipeline by Carolus Therapeutics, Inc., H2 2015
  • Aortic Aneurysm - Pipeline by Novartis AG, H2 2015
  • Aortic Aneurysm - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Aortic Aneurysm Therapeutics - Recent Pipeline Updates, H2 2015
  • Aortic Aneurysm - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Aortic Aneurysm, H2 2015
  • Number of Products under Development for Aortic Aneurysm - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top